(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Acute myeloid leukemia, cancer treatment, clinical trials, CXCR4, Dirk Pleimes, Eckert & Ziegler, EZR, Ga68-PentixaFor, GMP manufacturing, Harald Hasselmann, lymphoma, Myeloma, nuclear medicine, Pentixapharm, radiopharmaceuticals, radiotherapy, solid tumors, targeted therapy, theranostics, Y90-PentixaTher
(IN BRIEF) Basilea Pharmaceutica has received a CHF 1.7 million milestone payment from its partner Asahi Kasei Pharma following continued strong sales of Cresemba® in Japan—marking the second consecutive quarterly milestone. Cresemba, now marketed in over 70 countries, achieved USD … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AKP, antifungal treatment, Asahi Kasei Pharma, aspergillosis, azole antifungal, Basilea Pharmaceutica, biopharmaceuticals, branded antifungal leader, Cresemba®, cryptococcosis, David Veitch, fungal infection therapies, global antifungal sales, intravenous antifungal, invasive fungal infections, Isavuconazole, Japan pharmaceutical market, Japanese drug market, milestone payment, mucormycosis, oral antifungal, partnership
(IN BRIEF) Roche has launched a CE-marked Chest Pain Triage algorithm developed with Universitätsklinikum Heidelberg to improve emergency diagnosis of chest pain. Integrated into the navify® Algorithm Suite, the tool uses high-sensitivity cardiac troponin testing and ESC guidelines to support … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acute coronary syndrome, AI in healthcare, cardiac diagnostics, cardiovascular disease, CE-marked IVD, Chest Pain Triage Algorithm, digital diagnostics, digital health, EHR integration, emergency department, ESC guidelines, Healthcare Innovation, high-sensitivity troponin, hospital workflow optimization, Matt Sause, medical device, navify Algorithm Suite, patient triage, Roche, Universitätsklinikum Heidelberg
(IN BRIEF) CCRM Nordic is building a new ATMP production facility in GoCo Health Innovation City, Sweden, to support the development of next-generation gene, cell, and tissue-based therapies. AFRY will serve as engineering partner and project manager, leading the design, … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Sweden, Technology
Tagged advanced therapy medicinal products, AFRY, ATMP, biotechnology innovation, CCRM Nordic, cell therapy, engineering partner, Fredrik Wessberg, future-proof lab design, gene therapy, GMP compliance, GoCo Health Innovation City, Martin Öman, Mölndal, partnership, personalised medicine, pharmaceutical manufacturing, project management, sustainability, sustainable pharmaceutical production, Sweden healthcare strategy
(IN BRIEF) Boehringer Ingelheim has entered into a multi-year collaboration with Cue Biopharma to develop and commercialize CUE-501, a first-in-class bispecific compound designed to selectively deplete harmful B cells in autoimmune diseases. The innovative therapy uses Cue’s Immuno-STAT™ platform to … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged autoimmune diseases, B cell depletion, biologics innovation, biopharma collaboration, bispecific compound, Boehringer Ingelheim, Carine Boustany, chronic disease treatment, Cue Biopharma, CUE-501, Daniel Passeri, drug development, Immuno-STAT, Immuno-STAT platform, immunology pipeline, inflammatory diseases, licensing agreement, memory T cells, milestone payments, partnership, precision medicine, royalty payments, strategic partnership, T cell engagers, targeted biologics, up-front payment
(IN BRIEF) At ESCMID Global 2025 in Vienna, AstraZeneca will present a comprehensive data package from its Vaccines & Immune Therapies portfolio, featuring 13 abstracts across oral and poster presentations. The Company aims to demonstrate its progress in developing innovative … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, AZD6563, Benjamin Moutier, bronchiectasis, COVID-19, ESCMID Global 2025, Fluenz, FluMist, hMPV, immunizations, infectious diseases, Klebsiella pneumoniae, monoclonal antibodies, mRNA, MRSA, preclinical data, Pseudomonas aeruginosa, Real-World Data, respiratory viral infections, RSV, serious bacterial infections, Staphylococcus aureus, Vaccines & Immune Therapies, variant-agnostic threshold, Vienna
(IN BRIEF) Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, achieves rapid and dose-dependent reductions of amyloid plaques in the brain, with significant biomarker improvements observed in fluid … Read the full press release
Posted in Austria, Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged AD/PD 2025 International Conference, Alzheimer’s disease, amyloid plaques, ARIA-E, biomarkers, Brainshuttle AD study, cognitive impairment, diagnostic solutions, dose-dependent reduction, Elecsys pTau181 plasma test, Levi Garraway, neurogranin, Phase Ib/IIa study, Phase III programme, pTau181, pTau217, Roche, total tau, trontinemab
(IN BRIEF) Effective 3 April 2025, Novo Nordisk will undergo key changes in its Executive Management. Camilla Sylvest, a long-time leader with 28 years at the company, has decided to step down. In response, Ludovic Helfgott will assume expanded responsibilities … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged appointment, Camilla Sylvest departure, executive management, Executive Team, Global Communication, IT & Environmental Affairs, leadership, Leadership changes, Ludovic Helfgott, Novo Nordisk, organizational restructuring, Product & Portfolio Strategy, Quality, strategic leadership, Tania Sabroe, Thilde Hummel Bøgebjerg
(IN BRIEF) Rilzabrutinib, an investigational oral BTK inhibitor, has received orphan drug designation from the FDA for treating warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD), two rare conditions with no approved treatments. This designation, aimed at addressing unmet … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged BTK inhibitor, clinical trials, FDA, IgG4-RD, IgG4-related disease, immune thrombocytopenia, ITP, multi-immune modulation, orphan drug designation, phase 2a study, phase 2b study, rare diseases, regulatory review, rilzabrutinib, Sanofi, unmet medical need, wAIHA, warm autoimmune hemolytic anemia
(IN BRIEF) Boehringer Ingelheim, via its subsidiary NBE Therapeutics, has launched a cutting-edge ADC research and development facility in Basel with a CHF 27 million investment. The center is a key part of the company’s strategic efforts to advance next-generation … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged ADC, Basel, Boehringer Ingelheim, Cancer Therapies, CHF 27 million, DGNB Certificate Gold, Jean Engela, Karl Penz, Kaspar Sutter, NBE Therapeutics, oncology research, Swiss biotech, Synaffix B.V., Vienna
(IN BRIEF) IO Biotech, a Danish med-tech company, has obtained €57.5 million in venture debt financing from the European Investment Bank, with backing from the European Commission’s InvestEU programme. The financing, structured in three committed tranches of up to €37.5 … Read the full press release
Posted in Banks, Denmark, European Union, Financial, Healthcare, Investment, Luxembourg, Pharma & Biotech, Technology
Tagged Amy Sullivan, cancer vaccine, clinical development, EIB, European Commission, immunotherapeutic, InvestEU, IO Biotech, IO102-IO103, Ioannis Tsakiris, market launch, med-tech, melanoma, oncology, Pharmaceutical, regulatory approval, T-Win® platform, venture debt
(IN BRIEF) A new White Paper, developed by the Centre for Assuring Autonomy at the University of York, the MPS Foundation, and the Bradford Institute for Health Research, warns that the benefits of AI in patient care could be lost … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI, AI decision-support tools, AI Integration, Bradford Institute for Health Research, burnout, Centre for Assuring Autonomy, clinician autonomy, Clinicians, healthcare technology, Improvement Academy, liability sink, MPS Foundation, NHS, patient care, product liability, Professor Gozie Offiah, Professor Ibrahim Habli, Professor Tom Lawton, real-world scenarios, regulatory reform, Shared CAIRE, University of York, white paper
(IN BRIEF) Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to address a significant public health issue. Designed to protect against primary and recurrent infections caused by Chlamydia … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged asymptomatic infection, chlamydia, Chlamydia trachomatis, Fast Track Designation, Griffith University, immunogenicity, infertility, Jean-François Toussaint, mRNA vaccine candidate, pelvic inflammatory disease, phase 1/2 clinical study, pregnancy complications, public health need, Queensland Government, safety, Sanofi, Translational Science Hub, University of Queensland, US Food and Drug Administration
(IN BRIEF) SymRelief® green is the latest innovation from Symrise, formulated to revolutionize sensitive skincare with a patented synergistic complex that combines biotech-derived bisabolol and organic ginger root extract. This 100% Natural Origin Content solution, compliant with ISO 16128, delivers … Read the full press release
Posted in Apparel, Fashion & Beauty, Germany, Marketing, Pharma & Biotech
Tagged biodegradable, bisabolol, clinical efficacy, COL17A1, cosmetic ingredient, ginger root extract, halal, inflammaging, ISO 16128, kosher, natural origin content, responsible beauty, Sensitive Skin, sensitive skin solutions, skincare, sustainable, SymRelief® green, Symrise, vegan
(IN BRIEF) The EQT Foundation has opened a global call for proposals under its Breakthrough Science grants program, offering grants from €25,000 to €100,000 to researchers focused on addressing critical female health challenges with deeptech solutions. The initiative seeks to … Read the full press release
Posted in Business, Healthcare, Industrial, Investment, Pharma & Biotech, Sweden
Tagged 000, accredited institutions, Autoimmune Disorders, Breakthrough Science, cardiovascular diseases, commercialization, deeptech, diagnostics, endometriosis, EQT Foundation, female health challenges, financial support, global call for proposals, grants program, gynecological conditions, low-resource settings, maternal health, mentorship, Research & Innovation, therapeutics, Women’s Health
(IN BRIEF) The DataTools4Heart (DT4H) project, funded under the European Union’s Horizon Europe Framework, has successfully concluded its initial development phase and is set to achieve major milestones in 2025. Focused on enhancing the lifestyle of cardiovascular disease patients, DT4H … Read the full press release
Posted in Artificial Intelligence (AI), European Union, France, Healthcare, Industrial, Italy, Management, News, Pharma & Biotech, Science, Technology
Tagged AI-powered analytics, Barcelona Supercomputing Center, cardiology data reuse, cardiovascular disease, clinical data, clinician engagement, Cristian Izquierdo, data synthesis, DataTools4Heart, DT4H, eight hospitals, ESC Congress, European Union, federated learning, Horizon Europe, Laura G. Antiga, multilingual natural language processing, privacy-preserving, secure toolkit, Sophia Antipolis, stable software, unified interface, University of Barcelona
(IN BRIEF) Scientists at The Institute of Cancer Research in London have made significant strides in understanding why some cases of neuroblastoma—a pediatric cancer of nerve tissue—result in poorer outcomes. Their research indicates that mutations in the ATRX gene, which … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ATRX gene, Cancer Letters, Cancer Research UK, Dr Sally George, Federica Lorenzi, high-risk, immune cell infiltration, inflammatory pathways, macrophages, MYCN gene amplification, Neuroblastoma, Neuroblastoma UK, paediatric oncology, personalised therapy, targeted treatment, The Institute of Cancer Research, TIME, tumour immune microenvironment
(IN BRIEF) The ESC Preventive Cardiology 2025 Congress will be held in Milan from 3 to 5 April 2025 and is organized by the European Association of Preventive Cardiology, part of the ESC. The event will feature over 120 sessions … Read the full press release
Posted in Business, European Union, France, Healthcare, Industrial, Law, Management, News, Pharma & Biotech, Science
Tagged 3 April 2025, 5 April 2025, artificial intelligence, breakthrough interventions, cancer therapy-induced toxicity, cardiovascular disease, data science, diagnostics, digital cardiac rehabilitation, ESC Preventive Cardiology 2025, European Association of Preventive Cardiology, European Society of Cardiology, gender differences, heart health, interactive workshops, Italian Federation of Cardiology, Italian Strategic Plan for Cardiovascular Health, Italy, live cases, Milan, Nicolle Kränkel, Obesity, Pharmacology, press accreditation, press conference, preventive cardiology, primary prevention, public health, rehabilitation, risk estimation tools, secondary prevention, sports cardiology
(IN BRIEF) Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement aimed at supporting AtomVie’s radiopharmaceutical manufacturing efforts. Under this agreement, Eckert & Ziegler will provide its high-grade non-carrier added Lutetium-177 chloride (Theralugand®) … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology
Tagged AtomVie Global Radiopharma Inc, Bruno Paquin, CDMO, contract development, Dr. Harald Hasselmann, Eckert & Ziegler SE, global partnership, global supply agreement, GMP manufacturing, INNOVATION, life-saving therapies, non-carrier added Lutetium-177 chloride, nuclear medicine, radiopharmaceutical, radiopharmaceutical manufacturing, regulatory requirements, Theralugand®
(IN BRIEF) The Fresenius healthcare group is constructing a new facility, KabiLab D20, at Daimlerstrasse 20 on its Bad Homburg campus, set to cover 5,000 m². This modern laboratory and office building will feature state-of-the-art laboratories, 90 shared workstations, meeting … Read the full press release
Posted in Business, Construction, Environment, Financial, Germany, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged 000 m², 5, Bad Homburg, clinical nutrition leader, CO₂ reduction, Daimlerstrasse 20, Diabetes, employee relocation, Fresenius healthcare group, Fresenius Kabi Business Unit Nutrition, Fresubin enteral nutrition, heat pump, innovative products, KabiLab D20, laboratory and office building, metabolic disorders, Oberursel, patient-specific parenteral nutrition, Photovoltaic Systems, Rainwater harvesting, sustainability
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?